Product Images Gabapentin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Gabapentin NDC 51407-049 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
51407 047 90LB GABAPENTIN 100 MG CAPSULES REV NOV 2020 PMG NOV 2020 12 17 2020
This is a description of Gabapentin capsules with NDC code 51407-047-90. The capsules contain 100 mg of Gabapentin and come in a bottle of 90 capsules. Dosage instructions are provided in the package insert. The storage temperature range is between 20-28°C (68-82°F).*
51407 048 90LB GABAPENTIN 300 MG CAPSULES REV NOV 2020 PMG NOV 2020 12 31 2020
This is a description of gabapentin capsules, USP. Each capsule contains 300mg of gabapentin. The package includes 90 capsules and a Sese insert for dosage information. This medication should be kept out of reach of children and stored in a cool and dry place. The capsules are manufactured by Scleden Pharmaceuticals and packaged by GBMS, and are intended for distribution and dispensing to patients.*
51407 049 90LB GABAPENTIN 400 MG CAPSULES REV NOV 2020 PMG NOV 2020 12 17 2020
Figure 1 - image 01
This appears to be a table or chart with some numerical values related to pain scores and medication dosage. It is unclear what the context or purpose of this information is without further information.*
Figure 2 - image 02
This text describes a graph with a 4-week fixed dose period for Gabapentin and a placebo. The weeks are shown along the horizontal axis and the mean pain scores are shown along the vertical axis. The Gabapentin is administered at two different dosages, 1800mg/day and 2400mg/day. The graph shows the changes in mean pain scores over the 4-week period.*
Figure 3 - image 03
Cockcroft and Gault Equation - image 04
Gabapentin Structural Formula - image 05
Figure 4. Responder Rate in Patients Receiving gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - image 09
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.